Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Profit After Tax (2023 - 2025)

Contineum Therapeutics has reported Profit After Tax over the past 3 years, most recently at -$15.2 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$15.2 million for Q4 2025, down 4.21% from a year ago — trailing twelve months through Dec 2025 was -$60.0 million (down 41.98% YoY), and the annual figure for FY2025 was -$60.0 million, down 41.93%.
  • Profit After Tax for Q4 2025 was -$15.2 million at Contineum Therapeutics, down from -$12.8 million in the prior quarter.
  • Over the last five years, Profit After Tax for CTNM hit a ceiling of $41.6 million in Q2 2023 and a floor of -$16.0 million in Q2 2025.
  • Median Profit After Tax over the past 3 years was -$9.6 million (2024), compared with a mean of -$6.6 million.
  • Biggest five-year swings in Profit After Tax: tumbled 121.68% in 2024 and later decreased 4.21% in 2025.
  • Contineum Therapeutics' Profit After Tax stood at -$7.8 million in 2023, then tumbled by 87.48% to -$14.6 million in 2024, then dropped by 4.21% to -$15.2 million in 2025.
  • The last three reported values for Profit After Tax were -$15.2 million (Q4 2025), -$12.8 million (Q3 2025), and -$16.0 million (Q2 2025) per Business Quant data.